Overview
Ichiro Yajima practices practicing medicine in Saitama, Japan.
His clinical expertise encompasses Hearing Loss, Melanoma, Cerebellar Hypoplasia, and Neuroendocrine Tumor.
He is actively involved in clinical research, co-authoring 60 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Ichiro Yajima
Is Ichiro Yajima a top-rated expert for Hearing Loss?
MediFind is an objective health platform that identifies experts based on real-world data. Ichiro Yajima is classified as an Experienced expert for Hearing Loss, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Ichiro Yajima participate in research or clinical trials?
Yes. Ichiro Yajima has published 60 articles and abstracts on conditions like Hearing Loss. You can view a list of Ichiro Yajima's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Cerebellar HypoplasiaMr. Yajima isExperienced. Learn about Cerebellar Hypoplasia.
- Hearing LossMr. Yajima isExperienced. Learn about Hearing Loss.
- MelanomaMr. Yajima isExperienced. Learn about Melanoma.
- Neuroendocrine TumorMr. Yajima isExperienced. Learn about Neuroendocrine Tumor.